![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » FDA Rejects Y-mAbs Therapeutics BLA
FDA Rejects Y-mAbs Therapeutics BLA
December 5, 2022
The FDA has declined to approve Y-mAbs Therapeutics’ Biologics License Application (BLA) for its 131I-omburtamab candidate in treating central nervous system/leptomeningeal metastasis for patients with neuroblastoma, a type of cancer that forms in early nerve cells and usually develops in children under five years old.
In a Complete Response Letter to the company to explain why it could not approve the BLA, the agency said the supporting data did not demonstrate whether the drug candidate provides a clear benefit in overall survival.
The FDA recommended that the company meet with the agency to discuss a “well-controlled trial design to demonstrate substantial evidence of effectiveness and a favorable benefit-risk profile,” the company said.
Omburtamab was licensed to Y-mAbs Therapeutics by Memorial Sloan Kettering Cancer Center.
Upcoming Events
-
21Oct